Key facts
- This page summarizes John B. Moriarty Jr.'s Form 3 filing for Mirati Therapeutics, Inc..
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Jun 2023, 17:15.
John B. Moriarty Jr. - 23 Jun 2023 Form 3 Insider Report for Mirati Therapeutics, Inc.
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- N/A
- Reported as of
- 23 Jun 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 23 Jun 2023, 17:15:35 UTC
- Prior SEC filing
- 02 Feb 2023
- Next SEC filing
- 10 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Betsy Gelfand, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John B. Moriarty Jr. filed Form 3 for Mirati Therapeutics, Inc. on 23 Jun 2023.
Change
- Previous filing in this sequence was filed on 02 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 49,363
- Date
- 23 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRTX
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 23 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,525
- Exercise price
- $45.88
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date, which was May 1, 2023.
Footnote F2
25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was May 1, 2023 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.